NCT05690932 is a Phase 1 clinical trial of PBI-200 Tablet in Formulation Bridging, sponsored by Pyramid Biosciences.

Who is sponsoring NCT05690932?

NCT05690932 is sponsored by Pyramid Biosciences.

What drugs are being tested in NCT05690932?

Interventions in NCT05690932: PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension.

What condition does NCT05690932 study?

NCT05690932 studies Formulation Bridging, Food Effect.

Is NCT05690932 still recruiting?

NCT05690932 is currently completed. Last updated 1 February 2023.

Last reviewed 2023-02-01 · How we verify

NCT05690932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

Completed Phase 1 Last updated 1 February 2023

What this trial tests

Phase 1 trial testing PBI-200 Tablet in Formulation Bridging in 33 participants. Completed in 23 May 2022.

Timeline

24 February 2022

Primary endpoint
23 May 2022

23 May 2022

Quick facts

Lead sponsor	Pyramid Biosciences
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	24 February 2022
Primary completion	23 May 2022
Estimated completion	23 May 2022
Sites	1 location across United States

Drugs / interventions tested

PBI-200 Tablet — full drug profile →
PBI-200 Capsule
PBI-200 Suspension

Conditions studied

Formulation Bridging — all drugs for Formulation Bridging →
Food Effect — all drugs for Food Effect →

Sponsor

Pyramid Biosciences — full company profile →

Who can join

Adults 18 to 55, any sex, with Formulation Bridging or Food Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-dose, two-part, crossover formulation bridging and food effect study to assess the effect of formulation and food on the absorption and bioavailability of PBI-200 in normal, healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PBI-200 Tablet

Trials testing the same drug.

NCT05692570 — A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers · Phase 1 · completed

Other Pyramid Biosciences trials

Trials by the same sponsor.

NCT05692570 — A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers · Phase 1 · completed
NCT05238337 — A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200 · Phase 1 · completed
NCT05514353 — A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream · Phase 1 · completed
NCT05160389 — A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200 · Phase 1 · completed
NCT04901806 — Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05690932 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pyramid Biosciences
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05690932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing